French agency prioritizes innovation, drug safety and early access
This article was originally published in Scrip
Executive Summary
The French regulator ANSM has laid out a wide-ranging set of plans in its work program for 2015, including ensuring rapid and wider access to innovation, guaranteeing the safety of products throughout their life cycle, and using regulatory tools to speed up the availability of innovative new drugs.